Literature DB >> 26994250

Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases.

Ahmed K Alomari1, Justine Cohen2, Alexander O Vortmeyer3, Anne Chiang2, Scott Gettinger2, Sarah Goldberg2, Harriet M Kluger2, Veronica L Chiang4.   

Abstract

Delayed radiation-induced vasculitic leukoencephalopathy related to stereotactic radiosurgery (SRS) of brain metastases has been reported to manifest clinically 9 to 18 months after treatment. Immune-modulating therapies have been introduced to treatment regimens for malignancies with metastatic predilection to the brain. The interaction of these systemic therapies with other modalities of treatment for brain metastases, namely, SRS, has not been fully characterized. We report two patients with metastatic malignancies to the brain who received SRS followed by immunotherapy with monoclonal antibodies (mAb) to programmed death 1 (PD-1). Both patients appeared to have early clinical and radiologic progression of their treated lesions, which was highly suspicious for tumor progression. Both patients underwent surgical resection of their lesions and the material was submitted for histopathologic examination. Pathologic examination in both cases showed predominantly radiation-induced changes characterized by reactive astrocytosis and vascular wall infiltration by T lymphocytes. The accelerated response to SRS in these two patients was temporally related to the initiation of immunotherapy. We propose a possible biologic interaction between SRS and the PD-1 mAbs. Additionally, awareness of this potential occurrence is critical for accurate interpretation and proper management of clinical and radiologic findings in these patients. Cancer Immunol Res; 4(6); 481-7. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26994250     DOI: 10.1158/2326-6066.CIR-15-0238

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  22 in total

1.  Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.

Authors:  Harriet M Kluger; Veronica Chiang; Amit Mahajan; Christopher R Zito; Mario Sznol; Thuy Tran; Sarah A Weiss; Justine V Cohen; James Yu; Upendra Hegde; Elizabeth Perrotti; Gail Anderson; Amanda Ralabate; Yuval Kluger; Wei Wei; Sarah B Goldberg; Lucia B Jilaveanu
Journal:  J Clin Oncol       Date:  2018-11-08       Impact factor: 44.544

Review 2.  Immune checkpoint inhibitors in challenging populations.

Authors:  Douglas B Johnson; Ryan J Sullivan; Alexander M Menzies
Journal:  Cancer       Date:  2017-02-27       Impact factor: 6.860

Review 3.  Immune Checkpoint Inhibitors for Brain Metastases.

Authors:  Aaron C Tan; Amy B Heimberger; Alexander M Menzies; Nick Pavlakis; Mustafa Khasraw
Journal:  Curr Oncol Rep       Date:  2017-06       Impact factor: 5.075

4.  Histological changes associated with laser interstitial thermal therapy for radiation necrosis: illustrative cases.

Authors:  Elena I Fomchenko; Nalin Leelatian; Armine Darbinyan; Anita J Huttner; Veronica L Chiang
Journal:  J Neurosurg Case Lessons       Date:  2022-07-04

5.  The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.

Authors:  Paul W Sperduto; Wen Jiang; Paul D Brown; Steve Braunstein; Penny Sneed; Daniel A Wattson; Helen A Shih; Ananta Bangdiwala; Ryan Shanley; Natalie A Lockney; Kathryn Beal; Emil Lou; Thomas Amatruda; William A Sperduto; John P Kirkpatrick; Norman Yeh; Laurie E Gaspar; Jason K Molitoris; Laura Masucci; David Roberge; James Yu; Veronica Chiang; Minesh Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-03-29       Impact factor: 7.038

Review 6.  The Treatment of Melanoma Brain Metastases.

Authors:  Nour Kibbi; Harriet Kluger
Journal:  Curr Oncol Rep       Date:  2016-12       Impact factor: 5.075

7.  Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis.

Authors:  Jeffrey P Guenette; Raymond Y Huang; Pyeong Hwa Kim; Chong Hyun Suh; Ho Sung Kim; Kyung Won Kim; Dong Yeong Kim; Ayal A Aizer; Rifaquat Rahman
Journal:  Eur Radiol       Date:  2020-11-25       Impact factor: 5.315

Review 8.  History and current state of immunotherapy in glioma and brain metastasis.

Authors:  Tresa McGranahan; Gordon Li; Seema Nagpal
Journal:  Ther Adv Med Oncol       Date:  2017-02-01       Impact factor: 8.168

9.  Effect of Gamma Knife Radiosurgery and Programmed Cell Death 1 Receptor Antagonists on Metastatic Melanoma.

Authors:  Nathan Nordmann; Molly Hubbard; Tyler Nordmann; Paul W Sperduto; H Brent Clark; Matthew A Hunt
Journal:  Cureus       Date:  2017-12-13

Review 10.  The emerging role of epigenetic therapeutics in immuno-oncology.

Authors:  Michael J Topper; Michelle Vaz; Kristen A Marrone; Julie R Brahmer; Stephen B Baylin
Journal:  Nat Rev Clin Oncol       Date:  2019-09-23       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.